Zentalis Pharmaceuticals, Inc. (ZNTL) Investor Relations Documents

Zentalis Pharmaceuticals, Inc. (ZNTL) investor relations documents from the company's IR site: 3 presentations, 33 press releases; latest deck 2026-05-12. Read in-app with summaries. First-party data.

Download PDF file, (opens in new window): Zentalis Pharmaceuticals is developing azenosertib, an oral WEE1 inhibitor, targeting ~21,500 Cyclin E1-positive platinum-resistant ovarian cancer (PROC) patients.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseZentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Opt
2026-08-13Press releaseZentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
2026-08-13Press releaseZentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering
2026-08-06Press releaseZentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates
2026-08-03Press releaseZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-17Press releaseDownload , Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026, July 1
2026-07-17Press releaseZentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
2026-06-01Press releaseDownload , Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), June 1, 2026, (opens in new window)
2026-05-27Press releaseZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly a
2026-05-27Press releaseDownload , Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy, May 27, 2026, (opens in new window)
2026-05-21Press releaseZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety
2026-05-21Press releaseDownload , Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026, May 21, 2026, (opens in new window)
2026-05-13Press releaseDownload , Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences, May 13, 2026, (opens in new window)
2026-05-13Press releaseZentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-12Press releaseZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
2026-05-12Press releaseZentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
2026-05-12PresentationDownload PDF file, (opens in new window)
2026-05-05Press releaseZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin
2026-05-05Press releaseZentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin
2026-05-01Press releaseZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-21Press releaseZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel
2026-04-21Press releaseZentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel
2026-04-17Press releaseZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysi
2026-04-17Press releaseZentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysi
2026-04-09Press releaseDownload , Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E
2026-04-08PresentationDownload PDF (opens in new window)
2026-04-01Press releaseZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-26Press releaseZentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates
2026-03-17Press releaseDownload , Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual
2026-02-18Press releaseDownload , Zentalis Pharmaceuticals To Participate In Upcoming Investor Conferences, February 18, 2026, (opens in new wi
2026-02-03Press releaseDownload , Zentalis Pharmaceuticals To Participate In Upcoming Investor Conference, February 3, 2026, (opens in new wind
2026-02-03Press releaseZentalis Pharmaceuticals To Participate In Upcoming Investor Conference
2026-01-09PresentationDownload PDF (opens in new window)
2026-01-06Press releaseDownload , Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the
2026-01-06Press releaseZentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenoserti
2025-11-10Press releaseZentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

ZNTL overview · ZNTL earnings · ZNTL financials · ZNTL KPIs · ZNTL ownership · ZNTL peers · ZNTL filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.